Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06395103CT.gov Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ewing Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zilovertamab Vedotin (this asset) | Merck Sharp & Dohme LLC | P1/2 | CC · 45 |
| Irinotecan | Milton S. Hershey Medical Center | P3 | BB |
| Nivolumab | Children's National Research Institute | P2 | B |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Nogitecan | Pfizer | P2 | B |
| Adriamycin | Children's National Research Institute | P2 | B |
| Nadravaleucel | Brenda Cooper, MD | P2 | B |
| Gemogenovatucel-T | Gradalis, Inc. | P3 | B |
| Palbociclib | Dana-Farber Cancer Institute | P2 | B |
+42 more in the Ewing Sarcoma cohort
Other indications for Zilovertamab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 64 |
| Richter Transformation | — | P2 | B · 60 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Zilovertamab Vedotin in Ewing Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zilovertamab-vedotin-ewing-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →